JP2021528367A - 免疫応答を誘導するための組成物 - Google Patents
免疫応答を誘導するための組成物 Download PDFInfo
- Publication number
- JP2021528367A JP2021528367A JP2020561892A JP2020561892A JP2021528367A JP 2021528367 A JP2021528367 A JP 2021528367A JP 2020561892 A JP2020561892 A JP 2020561892A JP 2020561892 A JP2020561892 A JP 2020561892A JP 2021528367 A JP2021528367 A JP 2021528367A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- administered
- immune response
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000001939 inductive effect Effects 0.000 title claims abstract description 15
- 230000028993 immune response Effects 0.000 title description 14
- 239000000427 antigen Substances 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 57
- 102000036639 antigens Human genes 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 28
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 28
- 229920001184 polypeptide Polymers 0.000 claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 230000021633 leukocyte mediated immunity Effects 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000013598 vector Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 4
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 4
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 4
- 239000002157 polynucleotide Substances 0.000 claims abstract description 4
- 241001212582 Ancara Species 0.000 claims abstract 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 16
- 230000005867 T cell response Effects 0.000 claims description 12
- 238000002255 vaccination Methods 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 13
- 238000009169 immunotherapy Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 206010072219 Mevalonic aciduria Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 101150046614 C15L gene Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 101100280283 Vaccinia virus (strain Copenhagen) F11L gene Proteins 0.000 description 2
- 101100280285 Vaccinia virus (strain Western Reserve) VACWR050 gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 102220059024 rs747802641 Human genes 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 101150044104 soc gene Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229940032310 PROSTVAC vaccine Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 102000006388 human trophoblastic glycoprotein 5T4 Human genes 0.000 description 1
- 108010083654 human trophoblastic glycoprotein 5T4 Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 229940023867 prime-boost vaccine Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940030749 prostate cancer vaccine Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
[実施例]
5T4抗原ポリペプチドをコードするコドン最適化ポリヌクレオチド(NCBI Reference Sequence: NM_006670.4)を、GeneArt Gene Synthesis(Thermo Fisher Scientific社)によって合成した。次いで、5T4導入遺伝子を、相同配列アームとしてF11L ORFの上流と下流(隣接)を有するように設計したシャトルプラスミドベクターにクローン化した。これらのアーム内に5T4導入遺伝子を挿入することにより、右相同アームの一部である内在性F11プロモーターの利用を可能とし、一方、天然F11L ORFを欠失させた。この結果、MVA.(F11)5T4を生成するためのシャトルベクター(F11シャトルベクター)が得られた。
6匹の雄C57BL/6マウス(Harlan社、UK)の群は、1×1010VPのChAdOx1.5T4(群1〜3)又は1×107pfuのMVA.(F11)5T4(群4)の筋肉内(i.m.、intramuscular)投与からなるプライム免疫を0日目に受けた。
MVA−(F11)5T4を、後期転移性前立腺がんを治療するための治験でヒト対象に投与した。
Claims (32)
- 前立腺がんの治療又は予防のためのT細胞媒介免疫応答を誘導するための組成物であって、ポックスウイルスF11プロモーターの制御下で5T4抗原ポリペプチドを発現する改変ワクシニアウイルスアンカラ(MVA、modified Vaccinia virus Ankara)ベクターを含む、前記組成物。
- ポックスウイルスF11プロモーターが、内在性MVA F11プロモーターである、請求項1に記載の組成物。
- ベクターが、配列番号1のアミノ酸配列を有するポリペプチドを発現する、請求項1又は2に記載の組成物。
- ベクターが、配列番号2の核酸配列を有するポリヌクレオチドによってコードされるポリペプチドを発現する、請求項1又は2に記載の組成物。
- アジュバントをさらに含む、請求項1〜4のいずれかに記載の組成物。
- 5T4抗原ポリペプチドに対するT細胞媒介免疫応答の誘導に使用するための、請求項1〜5のいずれかに記載の組成物。
- T細胞媒介免疫応答がCD8+T細胞応答を含む、請求項6に記載の使用のための組成物。
- 前立腺がんの治療又は予防に使用するための、請求項1〜6のいずれかに記載の組成物。
- 対象において5T4抗原ポリペプチドに対するT細胞媒介免疫応答を誘導する方法であって、請求項1〜6のいずれかに記載の組成物を、前記対象に投与するステップを含む、前記方法。
- 組成物が、1×106〜5×108プラーク形成単位(pfu)の用量で投与される、請求項9に記載の方法。
- 組成物が、1×107pfuの用量で投与される、請求項10に記載の方法。
- T細胞媒介免疫応答がCD8+T細胞応答を含む、請求項9〜11のいずれかに記載の方法。
- 投与が、プライム−ブーストワクチン接種プロトコルの一部として実行される、請求項9〜12のいずれかに記載の方法。
- 投与が、以前のプライムワクチン接種へのブーストとして提供される、請求項13に記載の方法。
- 以前のプライムワクチン接種が、5T4抗原ポリペプチドを発現するアデノウイルスを投与するステップによって提供される、請求項14に記載の方法。
- アデノウイルスがChAdOx1である、請求項15に記載の方法。
- アデノウイルスが、1×108〜1×1012ウイルス粒子(VP)の用量で投与される、請求項15又は16に記載の方法。
- アデノウイルスが、1×109〜1×1011VPの用量で投与される、請求項17に記載の方法。
- アデノウイルスが、1×1010VPの用量で投与される、請求項18に記載の方法。
- 対象における前立腺がんの治療又は予防のためのT細胞媒介免疫応答を誘導する方法であって、請求項1〜6のいずれかに記載の組成物を、前記対象に投与するステップを含む、前記方法。
- 組成物が、1×106〜5×108プラーク形成単位(pfu)の用量で投与される、請求項20に記載の方法。
- 組成物が、1×107pfuの用量で投与される、請求項21に記載の方法。
- T細胞媒介免疫応答がCD8+T細胞応答を含む、請求項20〜22のいずれかに記載の方法。
- 投与が、プライム−ブーストワクチン接種プロトコルの一部として実行される、請求項20〜23のいずれかに記載の方法。
- 投与が、以前のプライムワクチン接種へのブーストとして提供される、請求項24に記載の方法。
- 以前のプライムワクチン接種が、5T4抗原ポリペプチドを発現するアデノウイルスを投与するステップによって提供される、請求項25に記載の方法。
- アデノウイルスがChAdOx1である、請求項26に記載の方法。
- アデノウイルスが、1×108〜1×1012VPの用量で投与される、請求項26又は27に記載の方法。
- アデノウイルスが、1×109〜1×1011VPの用量で投与される、請求項28に記載の方法。
- アデノウイルスが、1×1010VPの用量で投与される、請求項29に記載の方法。
- 免疫チェックポイント阻害剤化合物を投与するステップをさらに含む、請求項20〜30のいずれかに記載の方法。
- 免疫チェックポイント阻害剤化合物が、抗PD1モノクローナル抗体である、請求項31に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024078396A JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1807932.7A GB201807932D0 (en) | 2018-05-16 | 2018-05-16 | Compositions and methods for inducing an immune response |
GB1807932.7 | 2018-05-16 | ||
PCT/EP2019/062694 WO2019219851A1 (en) | 2018-05-16 | 2019-05-16 | Compositions for inducing an immune response |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024078396A Division JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021528367A true JP2021528367A (ja) | 2021-10-21 |
JPWO2019219851A5 JPWO2019219851A5 (ja) | 2022-05-18 |
Family
ID=62623405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020561892A Withdrawn JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
JP2024078396A Pending JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024078396A Pending JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210213060A1 (ja) |
EP (1) | EP3793581A1 (ja) |
JP (2) | JP2021528367A (ja) |
KR (1) | KR20210018295A (ja) |
CN (1) | CN112088012A (ja) |
AU (1) | AU2019270424A1 (ja) |
CA (1) | CA3097951A1 (ja) |
GB (1) | GB201807932D0 (ja) |
MX (1) | MX2020012150A (ja) |
SG (1) | SG11202010862VA (ja) |
WO (1) | WO2019219851A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113573729A (zh) | 2019-01-10 | 2021-10-29 | 詹森生物科技公司 | 前列腺新抗原及其用途 |
IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | calr and jak2 mutant-based vaccines and their uses |
EP4444347A1 (en) * | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
IN2015DN03326A (ja) * | 2012-10-28 | 2015-10-09 | Bavarian Nordic As |
-
2018
- 2018-05-16 GB GBGB1807932.7A patent/GB201807932D0/en not_active Ceased
-
2019
- 2019-05-16 KR KR1020207036057A patent/KR20210018295A/ko not_active Application Discontinuation
- 2019-05-16 CN CN201980030633.8A patent/CN112088012A/zh active Pending
- 2019-05-16 JP JP2020561892A patent/JP2021528367A/ja not_active Withdrawn
- 2019-05-16 CA CA3097951A patent/CA3097951A1/en active Pending
- 2019-05-16 SG SG11202010862VA patent/SG11202010862VA/en unknown
- 2019-05-16 AU AU2019270424A patent/AU2019270424A1/en active Pending
- 2019-05-16 US US17/055,056 patent/US20210213060A1/en active Pending
- 2019-05-16 EP EP19734251.2A patent/EP3793581A1/en active Pending
- 2019-05-16 WO PCT/EP2019/062694 patent/WO2019219851A1/en unknown
- 2019-05-16 MX MX2020012150A patent/MX2020012150A/es unknown
-
2024
- 2024-05-14 JP JP2024078396A patent/JP2024105526A/ja active Pending
Non-Patent Citations (5)
Title |
---|
ALHARBI N. K. ET AL., VACCINE, vol. 34, JPN6023014783, 2016, pages 49 - 55, ISSN: 0005037398 * |
AMATO R. J. ET AL., J. IMMUNOTHER., vol. 31, no. 6, JPN6023014781, 2008, pages 577 - 585, ISSN: 0005037397 * |
CAPPUCCINI F. ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 65, JPN6023014784, 2016, pages 701 - 713, ISSN: 0005037399 * |
HARROP R. ET AL., CLIN CANCER RES, vol. 12(11), JPN6023014787, 2006, pages 3416 - 3424, ISSN: 0005037400 * |
REDCHENKO I. ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15_suppl., JPN6023014788, 20 May 2018 (2018-05-20), pages 3018, ISSN: 0005037401 * |
Also Published As
Publication number | Publication date |
---|---|
CN112088012A (zh) | 2020-12-15 |
US20210213060A1 (en) | 2021-07-15 |
JP2024105526A (ja) | 2024-08-06 |
EP3793581A1 (en) | 2021-03-24 |
GB201807932D0 (en) | 2018-06-27 |
CA3097951A1 (en) | 2019-11-21 |
WO2019219851A1 (en) | 2019-11-21 |
SG11202010862VA (en) | 2020-11-27 |
AU2019270424A1 (en) | 2020-11-19 |
MX2020012150A (es) | 2021-04-28 |
KR20210018295A (ko) | 2021-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ladjemi et al. | Anti-HER2 vaccines: new prospects for breast cancer therapy | |
JP2024041809A (ja) | 癌を治療するための方法及び組成物 | |
Madan et al. | PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma | |
JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
US11235043B2 (en) | Vaccines against antigens involved in therapy resistance and methods of using same | |
Cappuccini et al. | 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy | |
JP2021038225A (ja) | ネコ用がんワクチン | |
Pierini et al. | Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression | |
JP7384896B2 (ja) | 主要組織適合遺伝子複合(mhc)クラスii-発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
US20180282736A1 (en) | Her3 vaccine vector compositions and methods of using the same | |
Neukirch et al. | Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice | |
JP2022553192A (ja) | 癌ワクチン | |
Wang et al. | Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model | |
Addeo et al. | A new generation of vaccines in the age of immunotherapy | |
Chen et al. | Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver | |
Edlich et al. | Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge | |
Naz et al. | Prophylactic vaccines for prevention of prostate cancer | |
Aremu et al. | Immunotherapy for head and neck cancers | |
Gupta et al. | Immunotherapy for Cancer: Strategies of Immunomodulation Therapy in Combination with Conventional Approaches | |
Sharma et al. | Immunotherapy in Gynecological Malignancies | |
Arlen et al. | Current perspectives in prostate cancer vaccines | |
JPWO2019219851A5 (ja) | ||
Wang et al. | Modulatory effects of tumor-derived heat shock protein in DNA vaccination against nasopharyngeal carcinoma | |
Schlom et al. | Recombinant TRICOM-based therapeutic cancer vaccines: Lessons learned | |
Mitchell et al. | Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7–10 March 2002 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230417 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230712 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230911 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240115 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20240515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240520 |